Document is current
Any future updates will be listed below
-
Authors
Kohlgruber, Ayano C. https://orcid.org/0000-0001-6758-3966
Dezfulian, Mohammad H.
Sie, Brandon M. https://orcid.org/0000-0001-9405-1850
Wang, Charlotte I.
Kula, Tomasz
Laserson, Uri https://orcid.org/0000-0002-8429-7686
Larman, H. Benjamin https://orcid.org/0000-0001-7863-196X
Elledge, Stephen J. https://orcid.org/0000-0001-7923-6283
- License Information
-
More Information
Article History
Received: 5 November 2023
Accepted: 16 April 2024
First Online: 2 July 2024
Competing interests
: T.K. is a founder of and holds equity in T-Scan Therapeutics and Immune ID. S.J.E. is a founder of and holds equity in T-Scan Therapeutics, MAZE Therapeutics, ImmuneID and Mirimus, serves on the scientific advisory boards of Homology Medicines, ImmuneID, MAZE Therapeutics and T-Scan Therapeutics and is an advisor for MPM Capital, none of which affect this work. H.B.L. is a founder of and holds equity in Infinity Bioscience, Alchemab and ImmuneID and is an advisor to T-Scan Therapeutics. The other authors declare no competing interests.
